Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring specified RAS mutations, ECOG 0–1, generally without acceptable standard systemic options; a newly diagnosed pancreatic ductal adenocarcinoma cohort is also eligible. Patients receive oral ERAS-0015, a pan-RAS molecular glue that disrupts active RAS–effector interactions and inhibits MAPK signaling, alone or with other investigational anticancer agents.

ClinicalTrials.gov ID: NCT06983743

A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors after progression on, or ineligibility for, standard therapies receive intravenous SIM0505 every 21 days. This CDH6-targeted antibody–drug conjugate delivers a topoisomerase-I inhibitor; dose optimization focuses on platinum-resistant ovarian, primary peritoneal or fallopian-tube cancer, clear-cell or papillary renal cell carcinoma, uterine serous carcinoma, and CDH6-expressing NSCLC adenocarcinoma without an actionable EGFR mutation.

ClinicalTrials.gov ID: NCT06792552

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial targets adult patients with non-small cell and small cell lung cancers experiencing oligo-progression while on stable systemic therapy, assessing the addition of locally ablative therapies like stereotactic ablative radiotherapy (SABR) and interventional radiology ablation for up to five or fewer metastatic lesions.

ClinicalTrials.gov ID: NCT06103682

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors after prior therapy, or who cannot receive or decline standard treatment, and ECOG performance status 0–1 receive single-agent intravenous CPO301 every 3 weeks. Dose expansion focuses on EGFR-mutant non-small-cell lung cancer; CPO301 is an EGFR-targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT05948865

A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or metastatic EGFR-mutant NSCLC after EGFR-TKI therapy, with or without up to one platinum-based chemotherapy regimen, receive once-daily oral JIN-A02; expansion cohorts require prior treatment with a T790M-active EGFR-TKI. JIN-A02 is an investigational, reversible, mutant-selective EGFR inhibitor designed to target resistance mutations including C797S and T790M.

ClinicalTrials.gov ID: NCT05394831

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial investigates the safety and efficacy of [68Ga]Ga DOTA-5G for imaging and [177Lu]Lu DOTA-ABM-5G for treatment, targeting the integrin αvβ6, in up to 40 patients with metastatic non-small cell lung cancer who have progressed after previous treatments.

ClinicalTrials.gov ID: NCT06228482

Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ECOG 0–1, measurable disease, and an injectable, biopsy-accessible lesion may receive intratumoral MEM-288 alone after standard therapy for selected advanced solid tumors, or with nivolumab after first progression on frontline PD-1/PD-L1–based therapy for advanced NSCLC. MEM-288 is an oncolytic adenovirus designed to lyse tumor cells and express interferon beta and a CD40-ligand construct to stimulate antitumor immunity; nivolumab inhibits PD-1.

ClinicalTrials.gov ID: NCT05076760

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial focuses on treatment-naïve patients with locally advanced or metastatic EGFR-mutated NSCLC (exon 19del or exon 21 L858R mutations) and investigates the effectiveness of enhanced versus standard dermatologic management in those treated with amivantamab, a bispecific antibody targeting EGFR and MET receptors, and lazertinib, an EGFR tyrosine kinase inhibitor.

ClinicalTrials.gov ID: NCT06120140

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with relapsed or refractory advanced solid tumors who have exhausted or are unlikely to benefit from standard therapy receive autologous CRX100, activated immune cells carrying a tumor-selective oncolytic vaccinia virus, alone or with pembrolizumab. Eligible patients need measurable disease and ECOG performance status 0–1.

ClinicalTrials.gov ID: NCT04282044

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with refractory solid tumors receive oral AOH1996, an investigational PCNA inhibitor that targets DNA replication and repair. An NSCLC cohort may continue EGFR-targeted therapy alongside AOH1996 if disease has been stable or better on an EGFR inhibitor for at least two months.

ClinicalTrials.gov ID: NCT05227326